1
|
Raju L, Javan Nikkhah S, K M, Vandichel M, Eswaran R. Anticancer Potential of Dendritic Poly(aryl ether)-Substituted Polypyridyl Ligand-Based Ruthenium(II) Coordination Entities. ACS APPLIED BIO MATERIALS 2023; 6:4226-4239. [PMID: 37782900 DOI: 10.1021/acsabm.3c00452] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
This paper studies the anticancer potency of dendritic poly(aryl ether)-substituted polypyridyl ligand-based ruthenium(II) coordination entities. The dendritic coordination entities were successfully designed, synthesized, and characterized by different spectral methods such as Fourier transform infrared (FTIR), 1H and 13C- NMR, and mass spectrometry. Further, to understand the structure and solvation behavior of the coordination entities, we performed all-atom molecular dynamics (MD) simulations. The behavior, configuration, and size of the coordination entities in DMSO and water were studied by calculating the radius of gyration (Rg) and solvent-accessible surface area (SASA). The MTT assay was used to assess the in vitro cytotoxicity of all of the coordination entities against cancerous A549 (lung cancer cells), MDA MB 231 (breast cancer cells), and HepG2 (liver cancer cells) and was found to be good with comparable IC50 values with respect to the standard drug cisplatin. The coordination entities exhibited dose dependence, and the highest activity was shown against HepG2 cell lines in comparison to the other cancer cell lines. In addition, fluorescence staining studies, such as AO/EB, DAPI, and cell death analysis by PI staining, were performed on the coordination entities to understand the apoptosis mechanism. Furthermore, reactive oxygen species (ROS) and mitochondrial membrane potential (MMP) assays confirmed apoptosis in cancer cells via the mitochondrial pathway. The DNA fragmentation assay was done followed by molecular docking analysis with DNA executed to strengthen and support the experimental observations.
Collapse
Affiliation(s)
- Liju Raju
- Department of Chemistry, Madras Christian College (Autonomous), Affiliated to the University of Madras, Tambaram East, Chennai 600059, Tamilnadu, India
| | - Sousa Javan Nikkhah
- Department of Chemical Sciences, Bernal Institute, University of Limerick, Limerick V94 T9PX, Republic of Ireland
| | - MosaChristas K
- Department of Plant Biology and Biotechnology, Loyola Institute of Frontier Energy (LIFE), Loyola College (Autonomous), University of Madras, Chennai 600034, India
| | - Matthias Vandichel
- Department of Chemical Sciences, Bernal Institute, University of Limerick, Limerick V94 T9PX, Republic of Ireland
| | - Rajkumar Eswaran
- Department of Chemistry, Madras Christian College (Autonomous), Affiliated to the University of Madras, Tambaram East, Chennai 600059, Tamilnadu, India
| |
Collapse
|
2
|
Mignani S, Shi X, Rodrigues J, Tomas H, Karpus A, Majoral JP. First-in-class and best-in-class dendrimer nanoplatforms from concept to clinic: Lessons learned moving forward. Eur J Med Chem 2021; 219:113456. [PMID: 33878563 DOI: 10.1016/j.ejmech.2021.113456] [Citation(s) in RCA: 24] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2021] [Revised: 04/06/2021] [Accepted: 04/06/2021] [Indexed: 02/07/2023]
Abstract
Research to develop active dendrimers by themselves or as nanocarriers represents a promising approach to discover new biologically active entities that can be used to tackle unmet medical needs including difficult diseases. These developments are possible due to the exceptional physicochemical properties of dendrimers, including their biocompatibility, as well as their therapeutic activity as nanocarriers and drugs themselves. Despite a large number of academic studies, very few dendrimers have crossed the 'valley of death' between. Only a few number of pharmaceutical companies have succeeded in this way. In fact, only Starpharma (Australia) and Orpheris, Inc. (USA), an Ashvattha Therapeutics subsidiary, can fill all the clinic requirements to have in the market dendrimers based drugs/nancocarriers. After evaluating the main physicochemical properties related to the respective biological activity of dendrimers classified as first-in-class or best-in-class in nanomedicine, this original review analyzes the advantages and disavantages of these two strategies as well the concerns to step in clinical phases. Various solutions are proposed to advance the use of dendrimers in human health.
Collapse
Affiliation(s)
- Serge Mignani
- Université Paris Descartes, PRES Sorbonne Paris Cité, Laboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologique, 45, Rue des Saints Peres, CNRS UMR 860, 75006, Paris, France; CQM - Centro de Química da Madeira, MMRG, Universidade da Madeira, Campus da Penteada, 9020-105, Funchal, Portugal.
| | - Xangyang Shi
- CQM - Centro de Química da Madeira, MMRG, Universidade da Madeira, Campus da Penteada, 9020-105, Funchal, Portugal; College of Chemistry, Chemical Engineering and Biotechnology, Donghua University, Shanghai, 201620, PR China.
| | - João Rodrigues
- CQM - Centro de Química da Madeira, MMRG, Universidade da Madeira, Campus da Penteada, 9020-105, Funchal, Portugal.
| | - Helena Tomas
- CQM - Centro de Química da Madeira, MMRG, Universidade da Madeira, Campus da Penteada, 9020-105, Funchal, Portugal
| | - Andrii Karpus
- Laboratoire de Chimie de Coordination du CNRS, 205 Route de Narbonne, 31077, Toulouse Cedex 4, France; Université Toulouse, 118 Route de Narbonne, 31077, Toulouse Cedex 4, France
| | - Jean-Pierre Majoral
- Laboratoire de Chimie de Coordination du CNRS, 205 Route de Narbonne, 31077, Toulouse Cedex 4, France.
| |
Collapse
|
3
|
Mignani S, Shi X, Rodrigues J, Tomas H, Karpus A, Majoral JP. First-in-class and best-in-class dendrimer nanoplatforms from concept to clinic: Lessons learned moving forward. Eur J Med Chem 2021. [DOI: https://doi.org/10.1016/j.ejmech.2021.113456] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
4
|
|
5
|
Michlewska S, Maroto M, Hołota M, Kubczak M, Sanz Del Olmo N, Ortega P, Shcharbin D, de la Mata FJ, Bryszewska M, Ionov M. Combined therapy of ruthenium dendrimers and anti-cancer drugs against human leukemic cells. Dalton Trans 2021; 50:9500-9511. [PMID: 34254615 DOI: 10.1039/d1dt01388b] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Carbosilane ruthenium(ii) dendrimers have been complexed with conventional anti-cancer drugs. Due to its features, the presence of ruthenium within a dendrimer structure improves the anti-cancer properties of nanocomplexes containing 5-flurouracyl, methotrexate and doxorubicin. These dendrimers could be promising carriers of anti-cancer medicines. Ruthenium dendrimers that are positively charged can also enhance the cytotoxicity to cancer cells; moreover, they can form stable complexes with drugs. Results indicate that ruthenium dendrimers combined with doxorubicin and methotrexate significantly reduced the viability of leukaemia 1301 and HL-60 cancer cells.
Collapse
Affiliation(s)
- Sylwia Michlewska
- Laboratory of Microscopic Imaging & Specialized Biological Techniques. Faculty of Biology & Environmental Protection. University of Lodz, Banacha12/16, Lodz 90-237, Poland. and Department of General Biophysics. Faculty of Biology & Environmental Protection. University of Lodz, Pomorska 141/143, Lodz 90-236, Poland.
| | - Marta Maroto
- Universidad de Alcalá. Department of Organic and Inorganic Chemistry, and Research Institute in Chemistry "Andrés M. del Río" (IQAR), Madrid, Spain
| | - Marcin Hołota
- Department of General Biophysics. Faculty of Biology & Environmental Protection. University of Lodz, Pomorska 141/143, Lodz 90-236, Poland.
| | - Malgorzata Kubczak
- Department of General Biophysics. Faculty of Biology & Environmental Protection. University of Lodz, Pomorska 141/143, Lodz 90-236, Poland.
| | - Natalia Sanz Del Olmo
- Universidad de Alcalá. Department of Organic and Inorganic Chemistry, and Research Institute in Chemistry "Andrés M. del Río" (IQAR), Madrid, Spain
| | - Paula Ortega
- Universidad de Alcalá. Department of Organic and Inorganic Chemistry, and Research Institute in Chemistry "Andrés M. del Río" (IQAR), Madrid, Spain and Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Spain
| | - Dzmitry Shcharbin
- Institute of Biophysics & Cell Engineering of NASB, 220072 Minsk, Belarus
| | - Francisco Javier de la Mata
- Universidad de Alcalá. Department of Organic and Inorganic Chemistry, and Research Institute in Chemistry "Andrés M. del Río" (IQAR), Madrid, Spain and Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Spain
| | - Maria Bryszewska
- Department of General Biophysics. Faculty of Biology & Environmental Protection. University of Lodz, Pomorska 141/143, Lodz 90-236, Poland.
| | - Maksim Ionov
- Department of General Biophysics. Faculty of Biology & Environmental Protection. University of Lodz, Pomorska 141/143, Lodz 90-236, Poland.
| |
Collapse
|
6
|
Moffett S, Shiao TC, Mousavifar L, Mignani S, Roy R. Aberrant glycosylation patterns on cancer cells: Therapeutic opportunities for glycodendrimers/metallodendrimers oncology. WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY 2020; 13:e1659. [PMID: 32776710 DOI: 10.1002/wnan.1659] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/19/2020] [Revised: 05/25/2020] [Accepted: 06/07/2020] [Indexed: 01/29/2023]
Abstract
Despite exciting discoveries and progresses in drug design against cancer, its cure is still rather elusive and remains one of the humanities major challenges in health care. The safety profiles of common small molecule anti-cancer therapeutics are less than at acceptable levels and limiting deleterious side-effects have to be urgently addressed. This is mainly caused by their incapacity to differentiate healthy cells from cancer cells; hence, the use of high dosage becomes necessary. One possible solution to improve the therapeutic windows of anti-cancer agents undoubtedly resides in modern nanotechnology. This review presents a discussion concerning multivalent carbohydrate-protein interactions as this topic pertains to the fundamental aspects that lead glycoscientists to tackle glyconanoparticles. The second section describes the detailed properties of cancer cells and how their aberrant glycan surfaces differ from those of healthy cells. The third section briefly describes the immune systems, both innate and adaptative, because the numerous displays of cell surface protein receptors necessitate to be addressed from the multivalent angles, a strength full characteristic of nanoparticles. The next chapter presents recent advances in glyconanotechnologies, including glycodendrimers in particular, as they apply to glycobiology and carbohydrate-based cancer vaccines. This was followed by an overview of metallodendrimers and how this rapidly evolving field may contribute to our arsenal of therapeutic tools to fight cancer. This article is categorized under: Therapeutic Approaches and Drug Discovery > Emerging Technologies Nanotechnology Approaches to Biology > Nanoscale Systems in Biology Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease.
Collapse
Affiliation(s)
| | | | | | | | - René Roy
- Glycovax Pharma Inc, Montreal, Quebec, Canada
| |
Collapse
|
7
|
Affiliation(s)
- Shazia Parveen
- Faculty of Science, Chemistry Department Taibah University Yanbu Branch Yanbu 46423 Saudi Arabia
| |
Collapse
|
8
|
Sanz Del Olmo N, Bajo AM, Ionov M, García-Gallego S, Bryszewska M, Gómez R, Ortega P, de la Mata FJ. Cyclopentadienyl ruthenium(II) carbosilane metallodendrimers as a promising treatment against advanced prostate cancer. Eur J Med Chem 2020; 199:112414. [PMID: 32438200 DOI: 10.1016/j.ejmech.2020.112414] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2020] [Revised: 04/16/2020] [Accepted: 04/28/2020] [Indexed: 12/19/2022]
Abstract
In searching for efficient and selective antitumour drugs, a new family of carbosilane metallodendrimers functionalized with [Ru(η5-C5H5)(PTA)Cl] (PTA = 1,3,5-triaza-7-phosphatricyclo-[3.3.1.1] decane) is reported. Experiments of the biophysical characterization showed an ability to interact with biological membranes, as well as with proteins (e.g. human serum albumin) without affecting their usual biological activity. These metallodendrimers possessed potent and selective anticancer activity in vitro in a panel of tumour cell lines. Importantly, the first generation metallodendrimer, bearing 4 Ru(II) complexes, was remarkably active towards resistant prostate cancer cells, inhibiting both cell proliferation and metastasis to bone tissues. Such promising antitumour activity can be further improved when given with docetaxel, with in vitro cytotoxicity being in the nanomolar range. Furthermore, its intravenous administration to an advanced prostate cancer mice model inhibited tumour growth up to 25% and 45% when given 10 mg/kg/week and 7.5 mg/kg/4-5 days, respectively.
Collapse
Affiliation(s)
- Natalia Sanz Del Olmo
- Department of Organic and Inorganic Chemistry, Research Institute in Chemistry "Andrés M. del Río" (IQAR), University of Alcalá, Madrid, Spain
| | - Ana M Bajo
- Department of Biology of Systems, Biochemistry and Molecular Biology Unit, University of Alcalá, Madrid, Spain
| | - Maksim Ionov
- Department of General Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143, 90-236, Lodz, Poland
| | - Sandra García-Gallego
- Department of Organic and Inorganic Chemistry, Research Institute in Chemistry "Andrés M. del Río" (IQAR), University of Alcalá, Madrid, Spain
| | - Maria Bryszewska
- Department of General Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143, 90-236, Lodz, Poland
| | - Rafael Gómez
- Department of Organic and Inorganic Chemistry, Research Institute in Chemistry "Andrés M. del Río" (IQAR), University of Alcalá, Madrid, Spain; Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Spain and Institute "Ramón y Cajal" for Health Research (IRYCIS), Spain
| | - Paula Ortega
- Department of Organic and Inorganic Chemistry, Research Institute in Chemistry "Andrés M. del Río" (IQAR), University of Alcalá, Madrid, Spain; Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Spain and Institute "Ramón y Cajal" for Health Research (IRYCIS), Spain.
| | - F Javier de la Mata
- Department of Organic and Inorganic Chemistry, Research Institute in Chemistry "Andrés M. del Río" (IQAR), University of Alcalá, Madrid, Spain; Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Spain and Institute "Ramón y Cajal" for Health Research (IRYCIS), Spain.
| |
Collapse
|
9
|
Sanz del Olmo N, Carloni R, Ortega P, García-Gallego S, de la Mata FJ. Metallodendrimers as a promising tool in the biomedical field: An overview. ADVANCES IN ORGANOMETALLIC CHEMISTRY 2020. [DOI: 10.1016/bs.adomc.2020.03.001] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
|
10
|
Moreira T, Francisco R, Comsa E, Duban-Deweer S, Labas V, Teixeira-Gomes AP, Combes-Soia L, Marques F, Matos A, Favrelle A, Rousseau C, Zinck P, Falson P, Garcia MH, Preto A, Valente A. Polymer "ruthenium-cyclopentadienyl" conjugates - New emerging anti-cancer drugs. Eur J Med Chem 2019; 168:373-384. [PMID: 30826512 DOI: 10.1016/j.ejmech.2019.02.061] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2018] [Revised: 02/21/2019] [Accepted: 02/21/2019] [Indexed: 12/12/2022]
Abstract
In this work, we aimed to understand the biological activity and the mechanism of action of three polymer-'ruthenium-cyclopentadienyl' conjugates (RuPMC) and a low molecular weight parental compound (Ru1) in cancer cells. Several biological assays were performed in ovarian (A2780) and breast (MCF7, MDA-MB-231) human cancer derived cell lines as well as in A2780cis, a cisplatin resistant cancer cell line. Our results show that all compounds have high activity towards cancer cells with low IC50 values in the micromolar range. We observed that all Ru-PMC compounds are mainly found inside the cells, in contrast with the parental low molecular weight compound Ru1 that was mainly found at the membrane. All compounds induced mitochondrial alterations. PMC3 and Ru1 caused F-actin cytoskeleton morphology changes and reduced the clonogenic ability of the cells. The conjugate PMC3 induced apoptosis at low concentrations comparing to cisplatin and could overcame the platinum resistance of A2780cis cancer cells. A proteomic analysis showed that these compounds induce alterations in several cellular proteins which are related to the phenotypic disorders induced by them. Our results suggest that PMC3 is foreseen as a lead candidate to future studies and acting through a different mechanism of action than cisplatin. Here we established the potential of these Ru compounds as new metallodrugs for cancer chemotherapy.
Collapse
Affiliation(s)
- Tiago Moreira
- Centro de Química Estrutural, Faculdade de Ciências da Universidade de Lisboa, Campo Grande, 1749-016, Lisboa, Portugal; Centre of Molecular and Environmental Biology (CBMA), Department of Biology, University of Minho, Portugal. Campus de Gualtar, Braga, 4710-057, Portugal
| | - Rita Francisco
- Centro de Química Estrutural, Faculdade de Ciências da Universidade de Lisboa, Campo Grande, 1749-016, Lisboa, Portugal; Centre of Molecular and Environmental Biology (CBMA), Department of Biology, University of Minho, Portugal. Campus de Gualtar, Braga, 4710-057, Portugal
| | - Elisabeta Comsa
- Drug Resistance & Membrane Proteins Team, Molecular Microbiology and Structural Biochemistry Laboratory, CNRS-UCBL1 UMR 5086, IBCP, 69367, Lyon, France
| | - Sophie Duban-Deweer
- Laboratoire de la barrière hémato-encéphalique (LBHE), Plateau Spectrométrie de Masse de l'ARTois (SMART), Université d'Artois, EA 2465, Lens, F-62300, France
| | - Valérie Labas
- Plate-forme de Chirurgie et d'Imagerie pour la Recherche et l'Enseignement (CIRE), Pôle d'Analyse et d'Imagerie des Biomolécules (PAIB), PR China, INRA, CNRS, Université de Tours, IFCE, 37380, Nouzilly, France
| | - Ana-Paula Teixeira-Gomes
- Plate-forme de Chirurgie et d'Imagerie pour la Recherche et l'Enseignement (CIRE), Pôle d'Analyse et d'Imagerie des Biomolécules (PAIB), PR China, INRA, CNRS, Université de Tours, IFCE, 37380, Nouzilly, France
| | - Lucie Combes-Soia
- Plate-forme de Chirurgie et d'Imagerie pour la Recherche et l'Enseignement (CIRE), Pôle d'Analyse et d'Imagerie des Biomolécules (PAIB), PR China, INRA, CNRS, Université de Tours, IFCE, 37380, Nouzilly, France
| | - Fernanda Marques
- Centro de Ciências e Tecnologias Nucleares, Instituto Superior Técnico, Universidade de Lisboa, E.N.10, 2695-066, Bobadela LRS, Portugal
| | - António Matos
- Centro de Investigação Interdisciplinar Egas Moniz, Egas Moniz-Cooperativa de Ensino Superior CRL, Campus Universitário, Quinta da Granja, Monte de Caparica, 2829-511, Caparica, Portugal
| | - Audrey Favrelle
- Univ. Lille, CNRS, Centrale Lille, ENSCL, Univ. Artois, UMR 8181 - UCCS - Unité de Catalyse et Chimie du Solide, F-59000, Lille, France
| | - Cyril Rousseau
- Unity of Catalysis and Solid State Chemistry, UMR CNRS 8181, University of Artois, 62000, Lens, France
| | - Philippe Zinck
- Univ. Lille, CNRS, Centrale Lille, ENSCL, Univ. Artois, UMR 8181 - UCCS - Unité de Catalyse et Chimie du Solide, F-59000, Lille, France
| | - Pierre Falson
- Drug Resistance & Membrane Proteins Team, Molecular Microbiology and Structural Biochemistry Laboratory, CNRS-UCBL1 UMR 5086, IBCP, 69367, Lyon, France
| | - M Helena Garcia
- Centro de Química Estrutural, Faculdade de Ciências da Universidade de Lisboa, Campo Grande, 1749-016, Lisboa, Portugal
| | - Ana Preto
- Centre of Molecular and Environmental Biology (CBMA), Department of Biology, University of Minho, Portugal. Campus de Gualtar, Braga, 4710-057, Portugal
| | - Andreia Valente
- Centro de Química Estrutural, Faculdade de Ciências da Universidade de Lisboa, Campo Grande, 1749-016, Lisboa, Portugal.
| |
Collapse
|
11
|
Caminade AM, Majoral JP. Phosphorus dendrimers functionalised with nitrogen ligands, for catalysis and biology. Dalton Trans 2019; 48:7483-7493. [DOI: 10.1039/c9dt01305a] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Phosphorus dendrimers (dendrimers having one phosphorus atom at each branching point) possess versatile properties, depending on the type of their terminal functions.
Collapse
|
12
|
Desmecht A, Steenhaut T, Pennetreau F, Hermans S, Riant O. Synthesis and Catalytic Applications of Multi-Walled Carbon Nanotube-Polyamidoamine Dendrimer Hybrids. Chemistry 2018; 24:12992-13001. [DOI: 10.1002/chem.201802301] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2018] [Revised: 06/14/2018] [Indexed: 12/12/2022]
Affiliation(s)
- Antonin Desmecht
- Institute of Condensed Matter and Nanosciences, Molecules, Solids and Reactivity (IMCN/MOST); Université catholique de Louvain; Place Louis Pasteur 1 1348 Louvain-la-Neuve Belgium
| | - Timothy Steenhaut
- Institute of Condensed Matter and Nanosciences, Molecules, Solids and Reactivity (IMCN/MOST); Université catholique de Louvain; Place Louis Pasteur 1 1348 Louvain-la-Neuve Belgium
| | - Florence Pennetreau
- Institute of Condensed Matter and Nanosciences, Molecules, Solids and Reactivity (IMCN/MOST); Université catholique de Louvain; Place Louis Pasteur 1 1348 Louvain-la-Neuve Belgium
| | - Sophie Hermans
- Institute of Condensed Matter and Nanosciences, Molecules, Solids and Reactivity (IMCN/MOST); Université catholique de Louvain; Place Louis Pasteur 1 1348 Louvain-la-Neuve Belgium
| | - Olivier Riant
- Institute of Condensed Matter and Nanosciences, Molecules, Solids and Reactivity (IMCN/MOST); Université catholique de Louvain; Place Louis Pasteur 1 1348 Louvain-la-Neuve Belgium
| |
Collapse
|
13
|
Gouveia M, Figueira J, Jardim MG, Castro R, Tomás H, Rissanen K, Rodrigues J. Poly(alkylidenimine) Dendrimers Functionalized with the Organometallic Moiety [Ru(η⁵-C₅H₅)(PPh₃)₂]⁺ as Promising Drugs Against Cisplatin-Resistant Cancer Cells and Human Mesenchymal Stem Cells. Molecules 2018; 23:E1471. [PMID: 29914219 PMCID: PMC6100097 DOI: 10.3390/molecules23061471] [Citation(s) in RCA: 30] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2018] [Revised: 06/11/2018] [Accepted: 06/12/2018] [Indexed: 02/05/2023] Open
Abstract
Here and for the first time, we show that the organometallic compound [Ru(η⁵-C₅H₅)(PPh₃)₂Cl] (RuCp) has potential to be used as a metallodrug in anticancer therapy, and further present a new approach for the cellular delivery of the [Ru(η⁵-C₅H₅)(PPh₃)₂]⁺ fragment via coordination on the periphery of low-generation poly(alkylidenimine) dendrimers through nitrile terminal groups. Importantly, both the RuCp and the dendrimers functionalized with [Ru(η⁵-C₅H₅)(PPh₃)₂]⁺ fragments present remarkable toxicity towards a wide set of cancer cells (Caco-2, MCF-7, CAL-72, and A2780 cells), including cisplatin-resistant human ovarian carcinoma cell lines (A2780cisR cells). Also, RuCp and the prepared metallodendrimers are active against human mesenchymal stem cells (hMSCs), which are often found in the tumor microenvironment where they seem to play a role in tumor progression and drug resistance.
Collapse
Affiliation(s)
- Marisol Gouveia
- CQM-Centro de Química da Madeira, MMRG, Universidade da Madeira, Campus da Penteada, 9000-390 Funchal, Portugal.
| | - João Figueira
- Department of Chemistry, ScilifeLab, Umeå University, KBC-Building, Linnaeus väg 6, 90736 Umeå, Sweden.
| | - Manuel G Jardim
- CQM-Centro de Química da Madeira, MMRG, Universidade da Madeira, Campus da Penteada, 9000-390 Funchal, Portugal.
| | - Rita Castro
- CQM-Centro de Química da Madeira, MMRG, Universidade da Madeira, Campus da Penteada, 9000-390 Funchal, Portugal.
| | - Helena Tomás
- CQM-Centro de Química da Madeira, MMRG, Universidade da Madeira, Campus da Penteada, 9000-390 Funchal, Portugal.
| | - Kari Rissanen
- Department of Chemistry, University of Jyvaskyla, P.O. Box. 35, FI-40014 Jyväskylä, Finland.
| | - João Rodrigues
- CQM-Centro de Química da Madeira, MMRG, Universidade da Madeira, Campus da Penteada, 9000-390 Funchal, Portugal.
- School of Materials Science and Engineering/Center for Nano Energy Materials, Northwestern Polytechnical University, Xi'an 710072, China.
| |
Collapse
|
14
|
Gouveia M, Figueira J, Jardim M, Castro R, Tomás H, Rissanen K, Rodrigues J. Poly(alkylidenimine) Dendrimers Functionalized with the Organometallic Moiety [Ru(η5-C5H5)(PPh3)2]+ as Promising Drugs Against Cisplatin-Resistant Cancer Cells and Human Mesenchymal Stem Cells. Molecules 2018. [DOI: https://doi.org/10.3390/molecules23061471] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
|
15
|
Matsheku AC, Chen MYH, Jordaan S, Prince S, Smith GS, Makhubela BC. Acridine-containing RuII
, OsII
, RhIII
and IrIII
Half-Sandwich Complexes: Synthesis, Structure and Antiproliferative Activity. Appl Organomet Chem 2017. [DOI: 10.1002/aoc.3852] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Affiliation(s)
- Asanda C. Matsheku
- Department of Chemistry; University of Johannesburg; PO Box 524 Auckland Park 2006 South Africa
| | - Marian Y.-H. Chen
- Department of Chemistry; University of Cape Town; Rondebosch 7701 Cape Town South Africa
| | - Sandra Jordaan
- Department of Human Biology, Division of Cell Biology; University of the Cape Town; Cape Town South Africa
| | - Sharon Prince
- Department of Human Biology, Division of Cell Biology; University of the Cape Town; Cape Town South Africa
| | - Gregory S. Smith
- Department of Chemistry; University of Cape Town; Rondebosch 7701 Cape Town South Africa
| | | |
Collapse
|
16
|
Stringer T, De Kock C, Guzgay H, Okombo J, Liu J, Kanetake S, Kim J, Tam C, Cheng LW, Smith PJ, Hendricks DT, Land KM, Egan TJ, Smith GS. Mono- and multimeric ferrocene congeners of quinoline-based polyamines as potential antiparasitics. Dalton Trans 2016; 45:13415-26. [DOI: 10.1039/c6dt02685k] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
A series of mono- and multimeric polyamine-containing ferrocenyl complexes bearing a quinoline motif were prepared.
Collapse
|
17
|
Gupta G, Oggu GS, Nagesh N, Bokara KK, Therrien B. Anticancer activity of large metalla-assemblies built from half-sandwich complexes. CrystEngComm 2016. [DOI: 10.1039/c6ce00139d] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|